DYADIC INTERNATIONAL INC Net Fee Amt
DYADIC INTERNATIONAL INC (DYAI) had Net Fee Amt of $260.32 as of 2026-09-11, per its S-1 filed 2026-09-11.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-11
- 2026-09-11: Net Fee Amt $260.32.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-11 | $260.32 S-1 · filed 2026-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |